Want to see IN:PANACEABIO full AI Analyst Report?
Top Page
Panacea Biotec Limited
(PANACEABIO)
Select Model
Select Model
Rating:47Neutral
Price Target:
₹382.00
▼(-13.31% Downside)
Action:Reiterated
Date:09/11/26
Overall score is held back primarily by weak profitability and persistently negative free cash flow, alongside bearish technical trends (price below key moving averages and negative MACD). The main offsetting positive is a conservative balance sheet with low leverage and stable equity, plus improved revenue versus FY2023.
Positive Factors
Revenue Recovery
Revenue has recovered substantially from FY2023 levels and continued to grow in FY2026, indicating renewed commercial traction across the company’s pharmaceutical and vaccine-related portfolio. Sustained top-line expansion can improve operating leverage and support reinvestment over the next several quarters.
Negative Factors
Persistent Unprofitability
The company’s revenue recovery has not yet translated into sustainable profits, with both EBIT and net income still negative in FY2026. Continued losses can constrain internally funded growth, weaken returns on the stable equity base, and limit financial progress unless margins improve.
Read all positive and negative factors
Positive Factors
Negative Factors
Revenue Recovery
Revenue has recovered substantially from FY2023 levels and continued to grow in FY2026, indicating renewed commercial traction across the company’s pharmaceutical and vaccine-related portfolio. Sustained top-line expansion can improve operating leverage and support reinvestment over the next several quarters.
Read all positive factors
Panacea Biotec Limited (PANACEABIO) vs. iShares MSCI India ETF (INDA)
Market Cap
₹24.11B
Dividend Yield0.56%
Average Volume (3M)8.24K
Price to Earnings (P/E)―
Beta (1Y)1.28
Revenue Growth10.26%
EPS Growth-162.02%
CountryIN
Employees2,149
SectorGeneral
Sector StrengthN/A
IndustryBiotechnology
Share Statistics
EPS (TTM)-1.16
Shares Outstanding61,250,744
10 Day Avg. Volume6,769
30 Day Avg. Volume8,243
Financial Highlights & Ratios
PEG Ratio9.41
Price to Book (P/B)2.16
Price to Sales (P/S)2.82
P/FCF Ratio-49.16
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Panacea Biotec Limited Business Overview & Revenue Model
Company Description
Established in 1984 and headquartered in New Delhi, India, Panacea Biotec Limited is a biotechnology company dedicated to the innovation, production, and commercialization of pharmaceuticals, vaccines, and biosimilars. Its primary market is India,...
How the Company Makes Money
Panacea Biotec makes money primarily by selling pharmaceutical products and vaccines/biologics-related products. Key revenue streams typically include: (1) product sales of finished-dose pharmaceutical formulations (such as branded/generic prescri...
Panacea Biotec Limited Financial Statement Overview
Summary
Income Statement
44
Neutral
Balance Sheet
73
Positive
Cash Flow
38
Negative
| Breakdown | TTM | Mar 2026 | Mar 2025 | Mar 2024 | Mar 2023 | Mar 2022 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 6.73B | 6.40B | 5.59B | 5.52B | 4.57B | 6.59B |
| Gross Profit | 2.12B | 1.45B | 3.60B | 446.53M | 1.78B | 3.42B |
| EBITDA | 112.90M | -46.60M | 307.40M | 415.37M | 563.65M | 16.74B |
| Net Income | -71.20M | -53.70M | -83.70M | -11.73M | -332.37M | 10.78B |
Balance Sheet | ||||||
| Total Assets | 0.00 | 12.62B | 12.90B | 12.41B | 12.71B | 17.59B |
| Cash, Cash Equivalents and Short-Term Investments | 744.00M | 744.00M | 1.79B | 1.56B | 2.13B | 5.52B |
| Total Debt | 0.00 | 236.60M | 222.10M | 209.90M | 202.19M | 341.55M |
| Total Liabilities | -8.29B | 4.33B | 4.59B | 4.02B | 4.31B | 8.85B |
| Stockholders Equity | 8.29B | 8.35B | 8.35B | 8.42B | 8.44B | 8.77B |
Cash Flow | ||||||
| Free Cash Flow | -260.70M | -367.50M | -776.80M | -778.18M | -4.63B | -1.21B |
| Operating Cash Flow | -7.70M | 173.40M | -273.70M | -1.00M | -4.22B | -1.08B |
| Investing Cash Flow | -153.90M | -455.70M | 649.80M | 102.27M | 4.30B | 12.83B |
| Financing Cash Flow | -23.00M | 33.70M | -26.60M | -28.08M | -183.73M | -11.76B |
Panacea Biotec Limited Technical Analysis
Negative
440.65
Price Trends
442.51
Negative
448.19
Negative
400.60
Negative
Market Momentum
-13.26
Negative
40.53
Neutral
61.75
Neutral
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For IN:PANACEABIO, the sentiment is Negative. The current price of 440.65 is above the 20-day moving average (MA) of 396.34, below the 50-day MA of 442.51, and above the 200-day MA of 400.60, indicating a bearish trend. The MACD of -13.26 indicates Negative momentum. The RSI at 40.53 is Neutral, neither overbought nor oversold. The STOCH value of 61.75 is Neutral, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for IN:PANACEABIO.
Panacea Biotec Limited Peers Comparison
UnderperformOutperform
Sector (55)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
76 Outperform | ₹153.24B | 55.37 | ― | 0.52% | -6.72% | -22.67% | |
71 Outperform | ₹73.34B | 37.22 | ― | 0.11% | 28.14% | 11.38% | |
67 Neutral | ₹290.37B | -89.66 | ― | 0.06% | 0.78% | -420.81% | |
55 Neutral | $6.65B | 3.83 | -15.92% | 6.20% | 10.91% | 7.18% | |
55 Neutral | ₹156.00B | 69.82 | ― | 0.33% | -3.41% | -56.45% | |
49 Neutral | ₹643.11B | 115.19 | ― | 0.13% | 9.83% | 5.07% | |
47 Neutral | ₹24.11B | -335.04 | ― | 0.56% | 10.26% | -162.02% |
* General Sector Average
IN:PANACEABIO
Panacea Biotec Limited
398.05
-27.40
-6.44%
IN:BIOCON
Biocon Limited
390.95
26.29
7.21%
IN:CONCORDBIO
Concord Biotech Ltd.
1,506.65
-118.52
-7.29%
IN:PPLPHARMA
Piramal Pharma Limited
211.25
10.60
5.28%
IN:SUPRIYA
Supriya Lifescience Limited
903.85
257.12
39.76%
IN:SYNGENE
Syngene International Ltd.
382.65
-279.68
-42.23%
Panacea Biotec Limited Corporate Events
Panacea Biotec Publishes Q1 FY2026 Unaudited Results in Newspapers
Aug 14, 2026
Panacea Biotec Limited has notified the stock exchanges that it has published extracts of its unaudited standalone and consolidated financial results for the quarter ended June 30, 2026 in Business Standard and Desh Sewak newspapers, in compliance...
Panacea Biotec Files SEBI Dematerialization Compliance Certificate for June Quarter
Jul 8, 2026
Panacea Biotec Limited has submitted a compliance certificate under Regulation 74(5) of the SEBI (Depositories and Participants) Regulations, 2018 for the quarter ended June 30, 2026. The certificate, issued by Skyline Financial Services Pvt. Ltd....
Panacea Biotec Confirms Stable Demat Share Base in June 2026
Jul 8, 2026
Panacea Biotec Limited reported to Indian stock exchanges and depositories that no shares of the company were dematerialized in June 2026, in line with regulatory reporting requirements under SEBI’s depositories and participants framework. D...
Panacea Biotec Closes Trading Window Ahead of Q1 FY27 Results
Jun 26, 2026
Panacea Biotec Limited has announced that its trading window will be closed for all designated persons and their immediate relatives from July 1, 2026, in line with the SEBI (Prohibition of Insider Trading) Regulations, 2015. The window will reope...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.